ObjectiveTo evaluate the efficacy and safety of Fufang Luobuma Pills combined with amiodarone in the treatment of coronary heart disease with ventricular arrhythmia.

MethodsThe literatures on Fufang Luobuma Pills combined with amiodarone in the treatment of coronary heart disease with ventricular arrhythmia were searched from PubMed, China National Knowledge Infrastructure(CNKI), China Biomedical Literature Database(CBM), VIP Database and WanFang Database by computer.The Cochrane Handbook 5.1.0 was used to evaluate the quality criteria of randomized controlled trials, and the quality and risk of bias of literatures were evaluated, and statistically analyzed using RevMan5.3 software.

ResultsA total of 1 033 patients in 9 studies were enrolled, which included 464 cases of treatment group and 569 cases of control group(464 cases of amiodarone group and 105 cases of propafenone group).The results of Meta-analysis showed that the total clinical effective rate of Fufang Luobuma Pills combined with amiodarone was higher than that of amiodarone alone(OR=5.46;95% CI:3.40-8.75;Z=7.04;P < 0.00001;I²=0%) or propafenone alone(OR=2.99;95% CI:1.48-6.07;Z=3.04;P=0.002;I²=0%).The number of ventricular premature beats(SMD=-1.39;95% CI:-1.61--1.17;Z=12.34;P=0.00001;I²=0%) and occurrence of short array ventricular tachycardia(SMD=-1.51;95% CI:-1.73--1.28;Z=13.16;P < 0.00001;I²=0%) in treatment group were significantly reduced compared with those in amiodarone group.The difference of the incidence rate of adverse reaction between two groups was not statistically significant(OR=0.94;95% CI:0.58-1.53;Z=0.25;P=0.80;I²=0%).

ConclusionsThe effects of Fufang Luobuma Pills combined with amiodarone in the treatment of coronary heart disease with ventricular arrhythmia is better and safer than that of amiodarone and propafenone alone.